Lacosamid har været godkendt i Den Europæiske Union som lægemiddel mod epilepsi under handelsnavnet Vimpat siden august 2008.
Lacosamide has been authorised in the European Union (EU) as an anti-epileptic medicine under the trade name Vimpat since August 2008.